

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Usuka et al.

Serial No.: To be assigned

Filed: December 11, 2001

For: System And Method For Predicting  
Chromosomal Regions That Control Phenotypic  
Traits

Group Art Unit: To be assigned

Examiner: To be assigned

Attorney Docket No.: 9080-016-999

5/2/02

#4  
Plunkett

1c503 U.S. PTO

10/015167



INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

In accordance with the duty of disclosure provisions of 37 C.F.R. §1.56, there is hereby provided certain information which the Examiner may consider material to the examination of the subject U.S. patent application. It is requested that the Examiner make this information of record if it is deemed material to the examination of the application.

1. Enclosures accompanying this Information Disclosure Statement are:

1a. ☒ A list of all patents, publications, applications, or other information submitted for consideration by the office.

1b. A legible copy of:

- ☐ Each U.S. patent application publication and U.S. and foreign patent;
- ☒ Each publication or that portion which caused it to be listed on the PTO-1449;
- ☐ For each cited pending U.S. application, the application specification including the claims, and any drawing of the application, or portion of the application which caused it to be listed on the PTO-1449 including any claims directed to that portion;
- ☐ all other information or portion which caused it to be listed on the PTO-1449.

1c. ☐ An English language copy of search report(s) from a counterpart foreign application or PCT International Search Report.

- 1d. ☐ Explanations of relevancy (ATTACHMENT 1(d), hereto) or English language abstracts of the non-English language publications.
2. ☒ This Information Disclosure Statement is filed under 37 C.F.R. §1.97(b):
- ☒ Within three months of the filing date of a national application other than a continued prosecution application under §1.53(d);
  - ☐ Within three months of the date of entry of the national stage as set forth in §1.491 in an international application;
  - ☐ Before the mailing of the first Office action on the merits;
  - ☐ Before the mailing of a first Office action after the filing of a request for continued examination under §1.114.
3. ☐ This Information Disclosure Statement is filed under 37 C.F.R. §1.97(c) after the period specified in 37 C.F.R. §1.97(b), but before the mailing date of any of a final action under 37 C.F.R. §1.113, a notice of allowance under 37 C.F.R. §1.311 or an action that otherwise closes prosecution in the application.

*(Check either Item 3a or 3b)*

- 3a. ☐ The Certification Statement in Item 5 below is applicable. Accordingly, no fee is required.
- 3b. ☐ The \$180.00 fee set forth in 37 C.F.R. §1.17(p) in accordance with 37 C.F.R. §1.97(c) is:
- ☐ enclosed
  - ☐ to be charged to Pennie & Edmonds LLP Deposit Account No. 16-1150.

*(Item 3b to be checked if any reference known for more than 3 months)*

4. ☐ This Information Disclosure Statement is filed under 37 C.F.R. §1.97(d) after the period specified in 37 C.F.R. §1.97(c), but on or before the date of payment of the issue fee.

The \$180.00 fee set forth in 37 C.F.R. §1.17(p) is:

- ☐ enclosed.
- ☐ to be charged to Pennie & Edmonds LLP Deposit Account No. 16-1150.

The Certification Statement in Item 5 below is applicable.

5. ☐ Certification Statement *(applicable if Item 3a or Item 4 is checked)*

*(Check either Item 5a or 5b)*

- 5a. ☐ In accordance with 37 C.F.R. §1.97(e)(1), it is certified that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.

- 5b. ☐ In accordance with 37 C.F.R. §1.97(e)(2), it is certified that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the undersigned after making reasonable inquiry, was known by any individual designated in 37 C.F.R. §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

6. ☐ This application is a continuation application under 37 C.F.R. §1.60 or §1.53(b) or (d).

*(Check appropriate Items 6a, 6b and/or 6c)*

- 6a. ☐ A Petition to Withdraw from issue under 37 C.F.R. §1.313(b)(5) is concurrently filed herewith.

- 6b. ☐ Copies of publications listed on Form PTO-1449 from prior application Serial No. \_\_, filed on \_\_, of which this application claims priority under 35 U.S.C. §120, are not being submitted pursuant to 37 C.F.R. §1.98(d).

- 6c. ☐ Copies of the publications listed on Form PTO-1449 were not previously cited in prior application Serial No. \_\_, filed on \_\_, and are provided herewith.

7. ☐ This is a Supplemental Information Disclosure Statement. *(Check either Item 7a or 7b)*

- 7a. ☐ This Supplemental Information Disclosure Statement under 37 C.F.R. §1.97(f) supplements the Information Disclosure Statement filed on \_\_. A bona fide attempt was made to comply with 37 C.F.R. §1.98, but inadvertent omissions were made. These omissions have been corrected herein. Accordingly, additional time is requested so that this Supplemental Information Disclosure Statement can be considered as if properly filed on \_\_.

- 7b. ☐ This Supplemental Information Disclosure Statement is timely filed within one (1) month of a PTO Notice under 37 C.F.R. §1.97(i).

8. ☐ In accordance with 37 C.F.R. §1.98, a concise explanation of what is presently understood to be the relevance of each non-English language publication is:

*( Check Item 8a, 8b, or 8c)*

- 8a. ☐ satisfied because all non-English language publications were cited on the enclosed English language copy of the PCT International Search Report or the search report from a counterpart foreign application indicating the degree of relevance found by the foreign office.

- 8b. ☐ set forth in the application.


- 8c. ☐ enclosed as an attachment hereto.

9. ☒ The Commissioner is authorized to charge any additional fee required or credit any overpayment for this Information Disclosure Statement and/or Petition to Pennie & Edmonds LLP Deposit Account No. 16-1150.

10. ☒ No admission is made that the information cited in this Statement is, or is considered to be, material to patentability nor a representation that a search has been made (other than a search report of a foreign counterpart application or PCT International Search Report if submitted herewith). 37 C.F.R. §§1.97(g) and (h).

Respectfully submitted,

Date December 11, 2001



Francis E. Morris  
PENNIE & EDMONDS LLP  
3300 Hillview Avenue  
Palo Alto, California 94304  
(650) 493 - 4935

(Reg No. 24,615)

Express Mail No.:EL 340 685 029 US

## LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.

9080-016-999

APPLICATION NO.

To be assigned

APPLICANT

Usuka et al.

FILING DATE

December 11, 2001

GROUP

To be assigned

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

## FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
					YES NO

## OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

AA	Risch, "Searching For Genetic Determinants In The New Millennium," 2000, Nature 405, pp 847-856.
AB	Lander and Schork, "Genetic Dissection Of Complex Traits," 1994, Science 265, pp 2037-2048.
AC	Tsao, "Evidence For Linkage Of A Candidate Chromosome 1 Region To Human Systemic Lupus Erythematosus," 1997, J. Clin. Invest. 99, pp 725-731.
AD	Tsao, "PARP Alleles Within The Linked Chromosomal Region Are Associated With Systemic Lupus Erythematosus," 1999, J. Clin. Invest. 103, pp 1135-1140.
AE	Criswell et al., "PARP Alleles and SLE: Failure To Confirm Association With Disease Susceptibility," 2000, J. Clin. Invest., 105, pp 1501-1502.
AF	Delrieu, et al., "POLY(ADP-RIBOSE) Polymerase Alleles In French Caucasians Are Associated Neither With Lupus Nor With Primary Antiphospholipid Syndrome," 1999, Arthritis & Rheumatism 42, pp 2194-2197.
AG	Mucenski, et al., "AKXD Recombinant Inbred Strains: Models For Studying The Molecular Genetic Basis Of Murine Lymphomas," 1986, Molecular & Cellular Biology 6, pp 4236-4243.
AH	Lindqvist, et al., "A Susceptibility Locus for Human Systemic Lupus Erythematosus (hSLE1) On Chromosome 2q," 2000, Journal of Autoimmunity 14, pp 169-178.
AI	Nadeau and Frankel, "The Roads From Phenotypic Variation To Gene Discovery: Mutagenesis Versus QTLs," 2000, Nature Genetics 25, pp 381-384.
AJ	Ewart, et al., "Quantitative Trait Loci Controlling Allergen-Induced Airway Hyperresponsiveness In Inbred Mice," 2000, Am J. Respir. Cell Mol. Biol. 26, pp 537-545.
AK	Karp, et al., "Identification of Complement Factor 5 As A Susceptibility Locus For Experimental Allergic Asthma," 2000, Nature Immunology 1, pp 221-226.
AL	Chrisp, et al., "Lifespan And Lesions In Genetically Heterogeneous (Four-way Cross) Mice: A New Model For Aging Research," 1996, Veterinary Pathology 33, pp 735-743.
AM	Wielowieyski, et al., "Tli1, A Resistance Locus For Carcinogen-Induced T-Lymphoma," 1999, Mammalian Genome 10, pp 623-627.
AN	Gilbert, et al., "Susceptibility of AKXD Recombinant Inbred Mouse Strains To Lymphomas," 1993, J. Virol. 67, pp 2083-2090.
AO	Mucenski, et al., "Identification Of A Common Ecotropic Viral Integration Site, Evi-1, In The DNA of AKXD Murine Myeloid Tumors," 1988, Molecular & Cellular Biology 8, pp 301-308.
AP	Williams, et al., "Natural Variation In Neuron Number In Mice Is Linked To A Major Quantitative Trait Locus On Chr 11," 1998, Journal of Neuroscience 18, pp 138-146.

AQ	Fisch, <i>et al.</i> , "A Generalization Of The Mixture Model In The Mapping Of Quantitative Trait Loci For Progeny From A Biparental Cross Of Inbred Lines," 1996, Genetics 143 pp 571-577.
AR	Luo, <i>et al.</i> , "Interval Mapping Of Quantitative Trait Loci In An F2 Population," 1992, Heredity 69 pp 236-242.
AS	Cox, <i>et al.</i> , "Loci On Chromosomes 2 (NIDDM1) and 15 Interact To Increase Susceptibility To Diabetes In Mexican Americans," Feb 1999, Nature Genetics, Vol. 21, pp 213-215.
AT	Jiang, <i>et al.</i> , "Mapping Quantitative Trait Loci With Dominant And Missing Markers In Various Crosses From Two Inbred Lines," 1997, Genetics, 101pp 47-58.
AU	Rozzo, <i>et al.</i> , "Evidence for an Interferon-Inducible Gene, <i>Ifi202</i> , in the Susceptibility to Systemic Lupus," Immunity, September 2001, Vol. 15 pp 435-443.
AV	Grupe, <i>et al.</i> , "In Silico Mapping of Complex Disease-Related Traits in Mice," ScienceReprint, June 8, 2001, Vol. 292 pp 1915-1918.
EXAMINER	
DATE CONSIDERED	
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	

Jc503 U.S. PRO  
 10/015167  
 12/11/01